Posts

JPM Day 3 had a cautiously optimistic outlook

In honor of JPM Week, you’re reading a special edition of our biotech newsletter...

STAT+: At JPM, Verve details plot to take genome editin...

STAT sat down with Verve Therapeutics CEO Sekar Kathiresan at #JPM24 to dig deep...

After grilling Fauci on Covid origins, House Republican...

Republicans want to explore tighter inspection and safety requirements for infec...

STAT+: Heated lawsuit between AdventHealth, MultiPlan a...

A lawsuit between a large hospital system and a dominant vendor that works for h...

Nearly 1 in 10 teens globally have used ‘budget Ozempic...

Nearly 1 in 10 adolescents have used non-prescription weight loss products, acco...

STAT+: Pharmalittle: We’re reading about Sanofi’s Olymp...

A 2020 FDA warning on the labeling that Singulair could cause aggression, agitat...

Advocates expect Supreme Court Idaho abortion decision ...

Activists on both sides of the abortion debate said they anticipate ongoing effo...

STAT+: Bayer’s promising menopause drug trial results h...

Bayer may soon join Astellas in offering an effective non-hormonal treatment for...

Opinion: Preventing health care violence in the ER requ...

Health care workers facing violence in the ER need more than just safety — they ...

STAT+: Morgan Health wants you to know it’s still here

JPMorgan's business unit Morgan Health, started to control its health care costs...

JPM Day 2 has arrived. Here are the can’t-miss moments ...

In honor of JPM Week, you’re reading a special edition of our biotech newsletter...

STAT+: FDA’s Peter Marks seems inclined to grant full a...

The FDA's Peter Marks joined STAT for an interview about accelerated approval an...

Anthony Fauci talked Covid in Congress in a nine-hour, ...

Anthony Fauci spent nine hours on Capitol Hill yesterday, talking Covid behind c...

STAT+: Pharmalittle: We’re reading about a GSK deal, a ...

GSK will purchase the asthma drug developer Aiolos Bio for $1 billion upfront, t...

STAT+: Nvidia says a biological revolution is happening...

Is now the moment when drug development, which for years has only gotten more di...

STAT+: JPM 2024: FogPharma’s new CEO, Mathai Mammen, un...

FogPharma CEO Mathai Mammen is taking the stage at #JPM24 Tuesday for what he’s ...